Edwards Lifesciences CORP Form 4 insider transactions

Daniel J. Lippis, a CVP at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

An Edwards Lifesciences executive, Donald E Bobo Jr, exercised stock options and sold shares on January 16, 2025, according to a recent SEC filing.

Daniel J. Lippis, a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

An Edwards Lifesciences executive, Donald E Bobo Jr., exercised stock options and sold shares on December 9, 2024, under a pre-arranged 10b5-1 trading plan.

An Edwards Lifesciences executive, Daveen Chopra, sold 1,750 shares of common stock at a price of $73.2701 per share on December 6, 2024.

Wayne Markowitz, a General Manager and Senior Vice President at Edwards Lifesciences, sold 583 shares of common stock at $73.27 per share on December 6, 2024.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Larry L. Wood, Global President TAVR & Surg at Edwards Lifesciences, reports the sale of 25,000 shares of common stock and adjustments to beneficial ownership.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Wayne Markowitz, GM & SVP, Surgical at Edwards Lifesciences, reports a disposition of 648 shares of common stock to cover tax obligations.

Andrew M. Dahl, SVP, Corporate Controller at Edwards Lifesciences, reports the acquisition of 2,920 shares of common stock on September 13, 2024.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Catherine M. Szyman, CVP of Critical Care at Edwards Lifesciences, reports acquisition and disposal of company stock on September 3, 2024.

Daveen Chopra, CVP at Edwards Lifesciences, reported the sale of 1,250 shares of common stock on August 20, 2024.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the acquisition and disposal of common stock on July 11, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

David T. Feinberg, a director at Edwards Lifesciences, reports the acquisition of 2,308 restricted stock units on July 10, 2024.

Catherine M. Szyman, CVP at Edwards Lifesciences, disposed of 258 shares of common stock on July 7, 2024, to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reported the disposal of 410 shares of common stock at a price of $92.32 on July 7, 2024.

Jean-Luc M. Lemercier, a CVP at Edwards Lifesciences, disposed of 82 shares of common stock on July 7, 2024, to cover tax obligations.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Scott Ullem, CFO of Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Bernard J. Zovighian, CEO of Edwards Lifesciences, amended a previous Form 4 filing to accurately reflect indirect beneficial ownership of common stock held within the company's 401(k) plan.

Donald E. Bobo Jr., a CVP at Edwards Lifesciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

CEO Bernard Zovighian sold 8,617 shares of Edwards Lifesciences Corp. common stock at $87.68 per share on May 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences' CFO, Scott Ullem, exercised stock options and sold shares on May 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Robert W.A. Sellers, SVP, Corporate Controller at Edwards Lifesciences, reported the disposal of 229 shares of common stock at a price of $86.72 on May 11, 2024.

Catherine M. Szyman, CVP at Edwards Lifesciences, disposed of 827 shares of common stock on May 11, 2024, to cover tax obligations.